Current Report Filing (8-k)
December 17 2018 - 7:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): December 17, 2018
Protalix
BioTherapeutics, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-33357
|
|
65-0643773
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
2 Snunit Street
|
20100
|
Science Park, POB 455
|
|
Carmiel, Israel
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number,
including area code +972-4-988-9488
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
¨
|
Written communication pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth
company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01. Other Events
On December 17, 2018, the Company issued a press release announcing
the completion of enrollment for the Company’s BRIDGE phase III clinical trial of pegunigalsidase
alfa (PRX-102) for the treatment of Fabry disease. Additionally, the Company provided an update on the enrollment for its BALANCE
and BRIGHT phase III clinical trials
. A copy of the press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PROTALIX BIOTHERAPEUTICS, INC.
|
|
|
|
Date: December 17, 2018
|
By:
|
/s/ Moshe Manor
|
|
Name:
|
Moshe Manor
|
|
Title:
|
President and
|
|
|
Chief Executive Officer
|
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Apr 2023 to Apr 2024